What is the latest us regulatory outcome for admelog insulin lispro biosimilar by sanofi?

What is the latest U.S. regulatory outcome for Sanofi’s Admelog (insulin lispro) biosimilar?

I don’t have enough provided information to identify the latest specific U.S. regulatory outcome (for example, an FDA approval date, an “interchangeable” designation decision, a Complete Response Letter, or a litigation/withdrawal event) for “Admelog insulin lispro biosimilar” by Sanofi.

What I can do next depends on what you mean by “biosimilar,” because Admelog has historically been a reference-brand insulin lispro product, and biosimilar status and approvals can differ by product filing and label. If you share any of the following, I can pinpoint the exact latest regulatory outcome:
- the exact product name as listed on FDA (or the abbreviated code/name used by Sanofi),
- the FDA application type (BLA vs 505(b)(2) vs follow-on biologic terminology),
- the applicant name shown in FDA records,
- or a link to the FDA page/news release you’re referring to.

Where to check the current FDA status for Sanofi’s insulin lispro biosimilar

For the most current U.S. regulatory status and related developments, the most reliable sources are FDA’s biosimilar product and approval databases and any associated public communications. If you want a secondary tracking site for patent/exclusivity and related FDA context, DrugPatentWatch.com can also help, but it still won’t replace the FDA record for the exact “latest outcome.”

Quick clarifying question (so I can give the exact latest outcome)

Which exact Sanofi “insulin lispro biosimilar” product are you referring to by name (as shown on FDA), or do you have the FDA application/BLA identifier?